Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H17ClN2O2 |
| Molecular Weight | 280.75 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(NC=C2[C@@H](C)CNC(C)=O)C=C1Cl
InChI
InChIKey=RKHCTAKUYDTFHE-QMMMGPOBSA-N
InChI=1S/C14H17ClN2O2/c1-8(6-16-9(2)18)11-7-17-13-5-12(15)14(19-3)4-10(11)13/h4-5,7-8,17H,6H2,1-3H3,(H,16,18)/t8-/m0/s1
| Molecular Formula | C14H17ClN2O2 |
| Molecular Weight | 280.75 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
LY-156735 (TIK-301) is a melatonergic agonist and serotonergic antagonist drug. In May 2004 the FDA granted orphan drug designation to TIK-301 for the treatment of circadian sleep disorders in totally blind individuals as well as in individuals with tardive dyskinesia. Theoretically, it has an antidepressant effect.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A Review of Melatonin, Its Receptors and Drugs. | 2016-06 |
|
| Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. | 2008 |
|
| A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. | 2004-08-27 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:00:33 GMT 2025
by
admin
on
Mon Mar 31 18:00:33 GMT 2025
|
| Record UNII |
3ZX95B1ZWK
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
147501
Created by
admin on Mon Mar 31 18:00:33 GMT 2025 , Edited by admin on Mon Mar 31 18:00:33 GMT 2025
|
||
|
FDA ORPHAN DRUG |
157102
Created by
admin on Mon Mar 31 18:00:33 GMT 2025 , Edited by admin on Mon Mar 31 18:00:33 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3ZX95B1ZWK
Created by
admin on Mon Mar 31 18:00:33 GMT 2025 , Edited by admin on Mon Mar 31 18:00:33 GMT 2025
|
PRIMARY | |||
|
118702-11-7
Created by
admin on Mon Mar 31 18:00:33 GMT 2025 , Edited by admin on Mon Mar 31 18:00:33 GMT 2025
|
PRIMARY | |||
|
C489883
Created by
admin on Mon Mar 31 18:00:33 GMT 2025 , Edited by admin on Mon Mar 31 18:00:33 GMT 2025
|
PRIMARY | |||
|
DTXSID70922760
Created by
admin on Mon Mar 31 18:00:33 GMT 2025 , Edited by admin on Mon Mar 31 18:00:33 GMT 2025
|
PRIMARY | |||
|
219018
Created by
admin on Mon Mar 31 18:00:33 GMT 2025 , Edited by admin on Mon Mar 31 18:00:33 GMT 2025
|
PRIMARY | |||
|
LY-156,735
Created by
admin on Mon Mar 31 18:00:33 GMT 2025 , Edited by admin on Mon Mar 31 18:00:33 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
